News blog

Minster Pharmaceuticals

  • BY: Andrew Hore |
  • POSTED: 06/07/2009 |

Positive peer study results for the treatment of migraine with aura using Minster Pharmaceuticals’ tonaberset have been published in The Lancet Neurology.

Minster has already announced the headline results from the study by Professor Jes Olesen, the Director of the Danish Headache Centre but the article includes the full clinical data. 

Professor David Dodick, from the Mayo Clinic Arizona, says in the publication that a treatment such as tonabersat would be “an important therapeutic advance”.

This is good news for Minster because a Phase IIb study last year failed to show that tonabersat had any effect on reducing migraines.

The positive news helped the share price recover 0.25p to 6.25p, which values Minster at £3.68m. There was £6.34m in the bank at the end of March 2009, which management believes will fund the company for at least two years. 

© 2024 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Browse by issue
All issues
Popular tags
All tags

betbrokers, financial, gold, health, leisure, media, mobile, resources, services, technology

AIM Micro feeds

Keep up to date with articles published at AIMMicro.com. Subscribe to AIM Micro RSS Feeds